Literature DB >> 28386407

Current tools available for the diagnosis of drug-resistant tuberculosis.

Christopher Gilpin1, A Korobitsyn1, K Weyer1.   

Abstract

Drug-resistant tuberculosis (DR-TB) poses a major threat to control of tuberculosis worldwide. Diagnosis and treatment of DR-TB are considerably more difficult than for drug-susceptible tuberculosis (TB) and require higher level infrastructure and proficiency from laboratory specialists and clinicians. The World Health Organization (WHO) End TB Strategy calls for early diagnosis and initiation of appropriate treatment of all persons of all ages with any form of drug-susceptible TB or DR-TB. This requires ensuring access to WHO-recommended rapid diagnostics and universal drug susceptibility testing (DST) for all persons with signs and symptoms of TB. There are a number of laboratory tools available for diagnosis of DR-TB, including phenotypic culture-based DST as well as molecular methods. Optimal and complementary use of the available diagnostic tools at the different levels of the tiered network of TB laboratories, as well as correct interpretation of the diagnostic results provided by them is critical for accurate and timely diagnosis of DR-TB thus enabling effective treatment and care of patients.

Entities:  

Keywords:  diagnosis; drug resistance; laboratory; tuberculosis

Year:  2016        PMID: 28386407      PMCID: PMC5375090          DOI: 10.1177/2049936116673553

Source DB:  PubMed          Journal:  Ther Adv Infect Dis        ISSN: 2049-9361


  10 in total

Review 1.  The ins and outs of Mycobacterium tuberculosis drug susceptibility testing.

Authors:  E C Böttger
Journal:  Clin Microbiol Infect       Date:  2011-06-01       Impact factor: 8.067

2.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

3.  Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis.

Authors:  Hans L Rieder; Armand Van Deun
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

4.  Defining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations.

Authors:  Priti Kambli; Kanchan Ajbani; Meeta Sadani; Chaitali Nikam; Anjali Shetty; Zarir Udwadia; Sophia B Georghiou; Timothy C Rodwell; Antonino Catanzaro; Camilla Rodrigues
Journal:  Diagn Microbiol Infect Dis       Date:  2015-01-29       Impact factor: 2.803

5.  Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.

Authors:  Catherine Vilchèze; Feng Wang; Masayoshi Arai; Manzour Hernando Hazbón; Roberto Colangeli; Laurent Kremer; Torin R Weisbrod; David Alland; James C Sacchettini; William R Jacobs
Journal:  Nat Med       Date:  2006-08-13       Impact factor: 53.440

6.  High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.

Authors:  Diana Machado; João Perdigão; Jorge Ramos; Isabel Couto; Isabel Portugal; Claudia Ritter; Erik C Boettger; Miguel Viveiros
Journal:  J Antimicrob Chemother       Date:  2013-03-28       Impact factor: 5.790

7.  ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates.

Authors:  Glenn P Morlock; Beverly Metchock; David Sikes; Jack T Crawford; Robert C Cooksey
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

Authors:  Kristian Ängeby; Pontus Juréen; Gunnar Kahlmeter; Sven E Hoffner; Thomas Schön
Journal:  Bull World Health Organ       Date:  2012-05-29       Impact factor: 9.408

9.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.

Authors:  G CANETTI; S FROMAN; J GROSSET; P HAUDUROY; M LANGEROVA; H T MAHLER; G MEISSNER; D A MITCHISON; L SULA
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

10.  Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Authors:  Matteo Zignol; Anna S Dean; Natavan Alikhanova; Sönke Andres; Andrea Maurizio Cabibbe; Daniela Maria Cirillo; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Ashaque Husain; Alamdar Hussain; Nazir Ismail; Mostofa Kamal; Mikael Mansjö; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Ejaz Qadeer; Leen Rigouts; Sabine Ruesch-Gerdes; Marco Schito; Mehriban Seyfaddinova; Alena Skrahina; Sabira Tahseen; William A Wells; Ya Diul Mukadi; Michael Kimerling; Katherine Floyd; Karin Weyer; Mario C Raviglione
Journal:  Lancet Infect Dis       Date:  2016-07-07       Impact factor: 25.071

  10 in total
  12 in total

1.  Detection of Isoniazid and Rifampin Resistance in Mycobacterium tuberculosis Clinical Isolates from Sputum Samples by High-Resolution Melting Analysis.

Authors:  Shadi Parsa; Atieh Yaghoubi; Nafiseh Izadi; Faezeh Sabet; Leila Babaei Nik; Mohammad Derakhshan; Seyed Abdolrahim Rezaee; Zahra Meshkat; Seyed Javad Hoseini; Saeid Amel Jmehdar; Fatemeh Kiani; Amin Samiei; Saman Soleimanpour
Journal:  Curr Microbiol       Date:  2022-07-19       Impact factor: 2.343

Review 2.  Types and functions of heterogeneity in mycobacteria.

Authors:  Eun Seon Chung; William C Johnson; Bree B Aldridge
Journal:  Nat Rev Microbiol       Date:  2022-04-01       Impact factor: 78.297

3.  New Paracyclophanylthiazoles with Anti-Leukemia Activity: Design, Synthesis, Molecular Docking, and Mechanistic Studies.

Authors:  Ashraf A Aly; Stefan Bräse; Alaa A Hassan; Nasr K Mohamed; Lamiaa E Abd El-Haleem; Martin Nieger; Nesrin M Morsy; Elshimaa M N Abdelhafez
Journal:  Molecules       Date:  2020-07-07       Impact factor: 4.411

4.  Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates of Mycobacterium tuberculosis by high-resolution melting analysis.

Authors:  Mehrandokht Sirous; Azar Dokht Khosravi; Mohammad Reza Tabandeh; Shokrollah Salmanzadeh; Nazanin Ahmadkhosravi; Sirus Amini
Journal:  Infect Drug Resist       Date:  2018-10-18       Impact factor: 4.003

5.  Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.

Authors:  Workineh Shibeshi; Anandi N Sheth; Addisu Admasu; Alemseged Beyene Berha; Zenebe Negash; Getnet Yimer
Journal:  BMC Pharmacol Toxicol       Date:  2019-05-23       Impact factor: 2.483

6.  Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples.

Authors:  Timothy C Rodwell; Daniela M Cirillo; Andrea M Cabibbe; Andrea Spitaleri; Simone Battaglia; Rebecca E Colman; Anita Suresh; Swapna Uplekar
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

7.  Development and performance of CUHAS-ROBUST application for pulmonary rifampicin-resistance tuberculosis screening in Indonesia.

Authors:  Bumi Herman; Wandee Sirichokchatchawan; Sathirakorn Pongpanich; Chanin Nantasenamat
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

8.  Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study.

Authors:  Se Hyun Kwak; Ji Soo Choi; Eun Hye Lee; Su Hwan Lee; Ah Young Leem; Sang Hoon Lee; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Joon Chang; Young Ae Kang
Journal:  Yonsei Med J       Date:  2020-12       Impact factor: 2.759

Review 9.  Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.

Authors:  Navisha Dookie; Azraa Khan; Nesri Padayatchi; Kogieleum Naidoo
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640

10.  Evaluation of Mycobacterium tuberculosis viability in OMNIgene-SPUTUM reagent upon multi-day transport at ambient temperature.

Authors:  Elisa Tagliani; Riccardo Alagna; Silva Tafaj; Hasan Hafizi; Daniela Maria Cirillo
Journal:  BMC Infect Dis       Date:  2017-10-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.